Regeneron Pharmaceuticals said the Food and Drug Administration has accepted its resubmitted application seeking approval of linvoseltamab for certain patients with the blood cancer multiple myeloma.

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

This was the stock's second consecutive day of losses.

What lessons can be learnt from treating Trump? Why is his proclamation of Regeneron's unproven and experimental antibody ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Six new drugs, including a treatment for patients with advanced breast cancer, have been approved for use by the NHS in ...

Mucinex knocked Vicks off the top spot for monthly TV ad impressions as pharma brands generated significant coverage from ...

In Honeywell International Inc. v. 3G Licensing, S.A., Appeal No. 23-1354, the Federal Circuit held that under the obviousness standard of 35 U.S.C.

Ebola cases in Uganda have risen to nine, while 265 other people were being monitored under quarantine, health authorities ...

The EV maker's investors have to weigh what the CEO’s bid to gain control of the ChatGPT creator means for his time and their ...